Glycodeoxycholate Sulfate
Glycodeoxycholate sulfate (GDCS) is a sulfated conjugate of glycodeoxycholic acid, a secondary bile acid. Bile acids are steroidal molecules synthesized in the liver from cholesterol that play a critical role in the digestion and absorption of dietary fats and fat-soluble vitamins in the small intestine. They undergo enterohepatic circulation, being reabsorbed and returned to the liver, with a portion excreted. Sulfation, as seen in GDCS, typically increases the hydrophilicity of bile acids, facilitating their excretion.[1]
Biological Basis
Section titled “Biological Basis”As a bile acid, glycodeoxycholate sulfate is integral to the body’s lipid metabolism. It is part of the complex array of metabolites found in human serum, which are the end products of cellular processes and environmental interactions.[1] The levels of such metabolites can be influenced by genetic variations, which are increasingly studied through genome-wide association studies (GWAS). [1] These studies aim to connect common genetic variants (SNPs) to quantitative trait loci (QTLs) that affect metabolite concentrations, providing insights into metabolic pathways and their regulation. [1]
Clinical Relevance
Section titled “Clinical Relevance”Variations in the levels of bile acids like glycodeoxycholate sulfate can be indicative of various physiological states or underlying health conditions. Dysregulation of bile acid metabolism is associated with liver diseases, cholestasis, and malabsorption syndromes. Research into metabolite profiles, including those of bile acids, helps identify biochemical parameters that are routinely measured in clinical settings.[2]Identifying genetic associations with specific metabolite levels, such as those related to glycodeoxycholate sulfate, can offer insights into the genetic predispositions to conditions affecting lipid metabolism or liver function.[1]
Social Importance
Section titled “Social Importance”The study of metabolites and their genetic determinants contributes significantly to personalized medicine. Understanding how common genetic variations influence the levels of metabolites like glycodeoxycholate sulfate can lead to earlier identification of individuals at risk for certain metabolic or liver-related diseases. This knowledge can also inform the development of targeted diagnostic tools and therapeutic strategies, ultimately improving public health outcomes and facilitating preventative healthcare approaches.[1]
Limitations
Section titled “Limitations”Generalizability and Cohort Specificity
Section titled “Generalizability and Cohort Specificity”Studies investigating genetic associations with traits like glycodeoxycholate sulfate often face challenges in generalizability due to the demographic characteristics of the cohorts analyzed. Many investigations are predominantly conducted in populations of European ancestry, specifically among middle-aged to elderly individuals.[3] This inherent lack of ethnic diversity and age representation means that findings may not accurately reflect genetic influences or their effect sizes in younger populations or individuals of other racial or ethnic backgrounds. [3] Furthermore, the selection of participants in some cohorts, where DNA samples might be collected at later examination points, can introduce a survival bias, potentially skewing the observed associations by favoring individuals who lived long enough to participate in subsequent examinations. [3]
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The discovery of genetic associations for traits such as glycodeoxycholate sulfate is subject to methodological and statistical limitations inherent in genome-wide association studies (GWAS). A primary concern is the moderate sample size in some cohorts, which can lead to insufficient statistical power to detect genetic variants with modest effect sizes, increasing the risk of false negative findings.[3] Conversely, the extensive number of statistical tests performed in GWAS increases the likelihood of false positive associations, necessitating rigorous replication in independent cohorts as the “gold standard” for validating findings. [3] Additionally, the coverage of genetic variation by older SNP arrays may be incomplete, meaning that true associations could be missed if the causal variants or highly correlated proxies were not genotyped or adequately imputed. [4] While imputation helps to infer missing genotypes, it can introduce error rates, typically between 1.46% and 2.14% per allele, which can affect the accuracy of the imputed data. [5]
Phenotypic Assessment and Confounding Influences
Section titled “Phenotypic Assessment and Confounding Influences”Accurate measurement and interpretation of glycodeoxycholate sulfate levels are complicated by variations in phenotypic assessment and the potential for confounding factors. Differences in assay methodologies and population demographics across studies can lead to variations in mean biomarker levels, making direct comparisons challenging.[6] Moreover, the choice of a specific biomarker as a proxy for a broader physiological function, such as using cystatin C for kidney function or TSHfor thyroid function, may not fully capture the underlying biology and could potentially reflect other physiological risks, like cardiovascular disease, beyond the intended scope.[7]A significant limitation is the frequent absence of detailed investigation into gene-environment interactions; genetic variants may exert their effects in a context-specific manner, with environmental factors like diet potentially modulating their influence on a phenotype.[8]Without accounting for these interactions, the full genetic architecture contributing to glycodeoxycholate sulfate levels remains incompletely understood.
Variants
Section titled “Variants”SLCO1B1(Solute Carrier Organic Anion Transporter Family Member 1B1) encodes a protein primarily expressed in the liver, where it facilitates the uptake of various endogenous compounds, including bile acids like glycodeoxycholate sulfate, as well as many drugs. Genetic variations, such asrs4149056 , rs12317268 , and rs35380692 , can affect the efficiency of this transporter, influencing how quickly compounds are cleared from the blood and processed by the liver. Reduced SLCO1B1 activity due to certain variants can lead to higher circulating levels of its substrates, including sulfated bile acids, potentially impacting their therapeutic or toxic effects. [9] Similarly, SLC10A2(Solute Carrier Family 10 Member 2), known as the apical sodium-dependent bile acid transporter (ASBT), is critical for the reabsorption of bile acids in the small intestine, playing a key role in the enterohepatic circulation. The variantrs55971546 may influence the function of this transporter, altering the absorption efficiency of bile acids from the gut lumen back into circulation. Changes inSLC10A2activity can impact the overall pool size and composition of bile acids, affecting lipid metabolism and potentially the availability of glycodeoxycholate sulfate for further processing.[1]
SULT2A1 (Sulfotransferase Family 2A Member 1) encodes a sulfotransferase enzyme, which is crucial for the sulfation of various endogenous substrates, including bile acids, steroids, and xenobiotics. This sulfation process typically enhances the water solubility of compounds, facilitating their excretion from the body. Variants such as rs62129966 and rs296361 in SULT2A1may lead to altered enzyme activity, affecting the rate at which glycodeoxycholate is sulfated, thus influencing its metabolic fate and excretion. Such genetic differences can modulate the body’s capacity to detoxify and eliminate sulfated metabolites.[3] The impact of these SULT2A1variants can extend to broader implications for liver health and systemic metabolism, as efficient bile acid sulfation is essential for maintaining bile acid homeostasis and protecting against cholestatic liver injury. Altered sulfation patterns could shift the balance of bile acid conjugates, affecting signaling pathways and contributing to variations in disease susceptibility or drug response, as evidenced by studies examining biomarker traits.[1]
UBXN2B(UBX Domain Protein 2B) is involved in protein degradation pathways, acting as a cofactor in ubiquitin-proteasome system-related processes. While its direct link to glycodeoxycholate sulfate metabolism is not as established as transporters or enzymes, its role in regulating protein turnover can indirectly influence cellular processes crucial for liver function and metabolic health. The variantrs1993453 could potentially alter the efficiency of these protein degradation pathways, leading to subtle changes in the levels or activities of other proteins that impact overall metabolic homeostasis and biomarker traits. [3] The region encompassing LRFN2(Leucine Rich Repeat And Fibronectin Type III Domain Containing 2) andUNC5CL (Unc-5 Netrin Receptor Like), with the variant rs184952051 , represents genes often associated with neurodevelopmental processes and cell adhesion. Although a direct mechanistic link to glycodeoxycholate sulfate is not immediately apparent, genetic variations in these types of regulatory genes can sometimes exert pleiotropic effects, indirectly impacting various physiological systems, including those involved in metabolic regulation or response to environmental factors, which can be explored through broad metabolomic screens.[1]
No information about ‘glycodeoxycholate sulfate’ is available in the provided context to generate the requested biological background section.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs4149056 rs12317268 rs35380692 | SLCO1B1 | bilirubin measurement heel bone mineral density thyroxine amount response to statin sex hormone-binding globulin measurement |
| rs62129966 rs296361 | SULT2A1 | estradiol measurement blood protein amount level of tetraspanin-8 in blood Glycochenodeoxycholate sulfate measurement X-12063 measurement |
| rs55971546 | SLC10A2 | level of tetraspanin-8 in blood Glycochenodeoxycholate sulfate measurement glycodeoxycholate sulfate measurement glycolithocholate sulfate measurement glycocholenate sulfate measurement |
| rs1993453 | UBXN2B | glycodeoxycholate sulfate measurement fatty acid amount |
| rs184952051 | LRFN2 - UNC5CL | glycodeoxycholate sulfate measurement |
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Orchestration of Lipid and Bile Acid Synthesis
Section titled “Metabolic Orchestration of Lipid and Bile Acid Synthesis”The synthesis and regulation of lipids, including cholesterol and fatty acids, form the foundational metabolic network from which derivatives like glycodeoxycholate sulfate emerge. Cholesterol, a crucial precursor for bile acids, is synthesized through the mevalonate pathway, with 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) acting as a key rate-limiting enzyme in this cascade. [10] Genetic variants influencing HMGCR activity can impact LDL-cholesterol levels, demonstrating a critical regulatory node in lipid homeostasis. [10] Concurrently, the composition of fatty acids, essential components of complex lipids such as phospholipids, is tightly controlled by enzymes like fatty acid desaturases 1 and 2 (FADS1, FADS2). These desaturases catalyze the conversion of specific fatty acids, for instance, delta-5 desaturase (catalyzed by FADS1) converts eicosatrienoyl-CoA (C20:3) to arachidonyl-CoA (C20:4), influencing the subsequent formation of phosphatidylcholines like PC aa C36:3 and PC aa C36:4. [1] The efficiency of these metabolic reactions, including desaturation and subsequent incorporation into phospholipids, is highly sensitive to genetic variations, which underscores the intricate flux control within these pathways. [1]
Genetic and Post-Translational Regulation of Metabolic Pathways
Section titled “Genetic and Post-Translational Regulation of Metabolic Pathways”Regulatory mechanisms profoundly influence the activity and availability of enzymes and transporters critical for lipid and metabolite processing. Gene regulation, including transcriptional control and post-translational modifications, dictates the cellular capacity for various metabolic tasks. For example, common single nucleotide polymorphisms (SNPs) within theHMGCR gene can affect the alternative splicing of its exon 13, leading to altered protein isoforms or expression levels, which in turn influences LDL-cholesterol levels. [10] Alternative splicing is a widespread regulatory mechanism, impacting protein function and cellular responses by generating diverse protein variants from a single gene. [10] Beyond genetic variants, protein modifications such as phosphorylation and allosteric control mechanisms also fine-tune enzyme activity, ensuring metabolic flexibility and responsiveness to physiological demands. These multi-layered regulatory strategies orchestrate the precise flow of metabolites through pathways, maintaining cellular and systemic homeostasis.
Membrane Transport and Metabolite Exchange Systems
Section titled “Membrane Transport and Metabolite Exchange Systems”Efficient transport systems are crucial for the movement of metabolites, including lipid derivatives and waste products, across cellular membranes and between tissues. The solute carrier family 2 member 9 (SLC2A9), also known as GLUT9, exemplifies such a critical transporter, primarily influencing serum uric acid levels and renal urate excretion.[11]This facilitative glucose transporter family member acts as a key urate anion exchanger, regulating blood urate levels and playing a significant role in conditions such as gout.[12] Genetic variants in SLC2A9are strongly associated with serum uric acid concentrations, exhibiting pronounced sex-specific effects on this physiological parameter.[11] While SLC2A9is specifically characterized for urate transport, its function highlights the broader principle of membrane transport systems in controlling the systemic concentrations of various endogenous metabolites, including those related to lipid and bile acid metabolism.
System-Level Integration and Disease Manifestation
Section titled “System-Level Integration and Disease Manifestation”The pathways governing lipid metabolism, gene regulation, and metabolite transport are not isolated but are extensively integrated through complex crosstalk and network interactions, contributing to emergent physiological properties and disease susceptibilities. For instance, dyslipidemia, characterized by abnormal levels of LDL-cholesterol, HDL-cholesterol, or triglycerides, results from the dysregulation of multiple interacting pathways, including those involvingHMGCR and genes influencing fatty acid composition. [5] Genetic variants across numerous loci collectively contribute to this polygenic dyslipidemia, highlighting the hierarchical regulation and compensatory mechanisms that attempt to maintain lipid homeostasis. [13]Understanding these systemic interactions provides insights into the pathogenesis of complex diseases like coronary artery disease and offers potential therapeutic targets, such as pharmacologically modulatingHMGCRactivity or influencing urate transporters likeSLC2A9to manage hyperuricemia.
References
Section titled “References”[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[2] Wallace, C et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.” Am J Hum Genet, 2008.
[3] Benjamin EJ. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, 2007. PMID: 17903293.
[4] O’Donnell CJ. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Med Genet, vol. 8, 2007. PMID: 17903303.
[5] Willer CJ, et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-169.
[6] Yuan X. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 5, 2008. PMID: 18940312.
[7] Hwang SJ. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Med Genet, vol. 8, 2007. PMID: 17903292.
[8] Vasan RS. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007. PMID: 17903301.
[9] Vitart V, et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 40, no. 4, 2008, pp. 437-442.
[10] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 11, 2008, pp. 2078-2086.
[11] Doring A, et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet, vol. 40, no. 4, 2008, pp. 430-436.
[12] Li S, et al. “The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.”PLoS Genet, vol. 3, no. 11, 2007, e194.
[13] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.